Due to the upregulation of the candidate biomarker XAGE1A in lung cancer tissues, which is inconsistent with its downregulated expression in plasma (Figure S2), we initially chose another candidate biomarker SLC16A4 for further analysis. The gene discussed is XAGE1A; the disease is lung carcinoma.